Read this manager's filing book
Disclosed positions
EcoR1 Capital, LLC: source evidence dated 2026-08-15T03:59:59.999Z.
- Issuer
- ZYMEWORKS INC
- Ticker
- ZYME
- Class
- COM
- Reported value
- $600,445,942
- Reported amount
- 22,970,388
- Unit
- SH
- Option
- None
The displayed owner or issuer and source fields identify the receipt to verify; keep reporting and availability dates separate.
What was reported for this quarter?
13F positions are dated quarter-end holdings, with later publication and possible amendments. Read report period and availability before calling them current.
SEC 13F-HR: 0000935836-26-000415Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filings
Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filingsKeep reporting dates and units beside the answer, and inspect its original citations.
Disclosed positions
See the complete disclosed positions
| ZYMEWORKS INC | ZYME | COM | $600,445,942 | 22,970,388 | SH | None |
| ANAPTYSBIO INC | ANAB | COM | $531,906,345 | 7,880,094 | SH | None |
| AKTIS ONCOLOGY INC | AKTS | COM | $155,492,636 | 4,824,469 | SH | None |
| CG ONCOLOGY INC | CGON | COM | $106,170,015 | 1,494,300 | SH | None |
| ETON PHARMACEUTICALS INC | ETON | COM | $78,624,156 | 2,171,938 | SH | None |
| CRISPR THERAPEUTICS AG | CRSP | NAMEN AKT | $75,771,113 | 1,389,276 | SH | None |
| ORIC PHARMACEUTICALS INC | ORIC | COM | $72,865,496 | 6,728,116 | SH | None |
| FIRST TRACKS BIOTHERAPEUTICS | TRAX | ORD SHS ADDED | $63,871,322 | 3,174,519 | SH | None |
| LAKEFRONT BIOTHERAPEUTICS NV | LKFT | SPON ADR | $49,980,228 | 1,667,119 | SH | None |
| NEUROGENE INC | NGNE | COM | $39,983,706 | 1,271,342 | SH | None |
| CG ONCOLOGY INC | CGON | COM | $39,894,575 | 561,500 | SH | Call |
| STOKE THERAPEUTICS INC | STOK | COM | $24,049,200 | 735,000 | SH | None |
| FULCRUM THERAPEUTICS INC | FULC | COM | $23,972,510 | 6,549,866 | SH | None |
| LEGEND BIOTECH CORP | LEGN | SPONSORED ADS | $23,104,000 | 800,000 | SH | None |
| BRIDGEBIO ONCOLOGY THERAPEUT | BBOT | COM NEW | $21,512,220 | 2,823,126 | SH | None |
| MBX BIOSCIENCES INC | MBX | COM | $21,445,200 | 388,500 | SH | None |
| ZENAS BIOPHARMA INC | ZBIO | COM | $20,037,510 | 789,500 | SH | None |
| ATARA BIOTHERAPEUTICS INC | ATRA | COM NEW | $17,816,960 | 1,552,000 | SH | None |
| RELAY THERAPEUTICS INC | RLAY | COM | $13,058,607 | 697,948 | SH | None |
| AURA BIOSCIENCES INC | AURA | COM | $11,833,336 | 1,666,667 | SH | None |
| ODYSSEY THERAPEUTICS INC | ODTX | COMMON STOCK ADDED | $10,394,434 | 555,555 | SH | None |
| EIKON THERAPEUTICS INC | EIKN | COM | $9,560,508 | 732,606 | SH | None |
| PHARVARIS N V | PHVS | COM | $8,126,300 | 235,000 | SH | None |
| ZURA BIO LTD | ZURA | CLASS A ORD SHS | $6,960,319 | 1,179,715 | SH | None |
| PHATHOM PHARMACEUTICALS INC | PHAT | COM | $6,781,250 | 625,000 | SH | None |
| NURIX THERAPEUTICS INC | NRIX | COM | $6,550,200 | 270,000 | SH | None |
| ERASCA INC | ERAS | COM | $6,045,600 | 330,000 | SH | None |
| ELOXX PHARMACEUTICALS INC | ELOX | COM NEW ADDED | $5,552,000 | 400,000 | SH | None |
| AARDVARK THERAPEUTICS INC | AARD | COM | $2,282,077 | 396,194 | SH | None |
| HELIX ACQUISITION CORP III USD | HLXC | CL A ORD SHS | $2,128,000 | 200,000 | SH | None |
| MEREO BIOPHARMA GROUP PLC | MREO | SPON ADS | $317,700 | 1,000,000 | SH | None |
| SURROZEN INC | Unresolved | *W EXP 08/01/203 | $115,322 | 4,444 | SH | None |
| AARDVARK THERAPEUTICS INC | AARD | COM | $84,672 | 14,700 | SH | Call |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 1 positions lack a resolved ticker and 2 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.